Citi has elevated its value goal for Akeso Inc (9926: HK) shares to HK$70.00, up from the earlier HK$64.00, whereas reiterating a Purchase ranking on the inventory.
The adjustment follows Akeso’s current presentation of optimistic HARMONi-2 research outcomes on the World Convention on Lung Most cancers (WCLC).
Akeso’s Ivonescimab demonstrated a big enchancment in median progression-free survival (mPFS) in sufferers with PD-L1 optimistic (TPS≥1%) non-small cell lung most cancers (NSCLC) when in comparison with pembrolizumab.
The research confirmed an mPFS of 11.14 months for Ivonescimab versus 5.82 months for pembrolizumab, with a hazard ratio (HR) of 0.51 and a p-value lower than 0.0001.
In line with the evaluation, the progression-free survival profit was constant throughout main medical subgroups. This included sufferers with each high and low PD-L1 expression ranges, and people with squamous or non-squamous superior NSCLC.
Moreover, Ivonescimab was reported to have a manageable security profile, with no grade 3 or larger hemorrhage noticed in sufferers with squamous NSCLC.
Citi’s report means that the compelling information surpasses market expectations and posits that the favorable PFS hazard ratio is more likely to translate right into a clinically significant total survival (OS) profit. This optimism is mirrored within the agency’s determination to boost the goal value for Akeso’s inventory.
This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.
